![]() For this purpose, we adapted the time-to-event pharmacokinetics (TITE-PK) model, which were originally developed for simultaneous investigation of multiple schedules. The aim is to utilize the information from both the completed and the ongoing schedules to inform decisions on the dose level for the next dose cohort. ![]() daily or weekly dosing) once the dose escalation with another schedule has been completed. Here, we consider sequential phase I trials, where the trial proceeds with a new schedule (e.g. ![]() More recently, however, multiple schedules are more frequently investigated in the same trial. Conventional methods for phase I dose-escalation trials in oncology are based on a single treatment schedule only.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |